Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida.

At MDA 2026, Sarepta will present new and ongoing evidence across its rare neuromuscular portfolio, including commercially available gene therapy and exon-skipping treatments in Duchenne muscular dystrophy. Presentations include a late-breaking oral presentation on delandistrogene moxeparvovec gene therapy from the Phase 3 EMBARK study (Part 1) up to three years post-infusion compared with a matched external control. Another abstract will feature caregiver-reported impressions from the Phase 3 EMBARK study through two years of follow-up, offering complementary perspectives on treatment impact beyond clinician-reported and performance-based outcomes. Additionally, a safety analysis of several delandistrogene moxeparvovec clinical studies with up to 7.5 years of patient follow-up will be presented; pooled data will include treatment-related adverse events that most commonly occurred within the first 60 days post-infusion.